现代肿瘤医学
現代腫瘤醫學
현대종류의학
JOURNAL OF MODERN ONCOLOGY
2015年
17期
2433-2436
,共4页
杨远游%程海明%宁健%穆晓峰
楊遠遊%程海明%寧健%穆曉峰
양원유%정해명%저건%목효봉
高龄%晚期非小细胞肺癌%伽马刀%复方红豆杉胶囊%疗效
高齡%晚期非小細胞肺癌%伽馬刀%複方紅豆杉膠囊%療效
고령%만기비소세포폐암%가마도%복방홍두삼효낭%료효
elderly%advanced non-small cell lung cancer%Gama-knife%Hongdoushan capsules%effectiveness
目的:分析伽马刀联合复方红豆杉胶囊治疗高龄晚期非小细胞肺癌的疗效。方法:2008年1月至2011年11月期间,我院收治的高龄晚期非小细胞肺癌15例采用伽马刀治疗+复方红豆杉胶囊0.6g口服3次/日,21天为1疗程,此后每月按疗程连续口服。伽马刀治疗以50%~80%等剂量曲线为处方剂量线,平均剂量(45.1667±4.7346)Gy/(6~14)f,3.5~8Gy/f,5f/w,1f/d。治疗结束后,每1~3月复查血常规、血生化、肿瘤标志物及影像学检查。随访3~60个月至2013年9月结束。结果:局部有效率( CR+PR)95.83%,中位生存期18个月(6~60个月),1、2、3、4、5年生存率分别为66.7%、33.3%、33.3%、6.7%、6.7%。消化道反应:I度1例、II度3例;血液学毒性:白细胞降低I度2例、II度1例,血小板降低I度1例、II度1例;放射性肺炎III级9例。结论:伽马刀联合复方红豆杉胶囊治疗高龄晚期非小细胞肺癌有效,可延长患者生存期,不良反应可接受。
目的:分析伽馬刀聯閤複方紅豆杉膠囊治療高齡晚期非小細胞肺癌的療效。方法:2008年1月至2011年11月期間,我院收治的高齡晚期非小細胞肺癌15例採用伽馬刀治療+複方紅豆杉膠囊0.6g口服3次/日,21天為1療程,此後每月按療程連續口服。伽馬刀治療以50%~80%等劑量麯線為處方劑量線,平均劑量(45.1667±4.7346)Gy/(6~14)f,3.5~8Gy/f,5f/w,1f/d。治療結束後,每1~3月複查血常規、血生化、腫瘤標誌物及影像學檢查。隨訪3~60箇月至2013年9月結束。結果:跼部有效率( CR+PR)95.83%,中位生存期18箇月(6~60箇月),1、2、3、4、5年生存率分彆為66.7%、33.3%、33.3%、6.7%、6.7%。消化道反應:I度1例、II度3例;血液學毒性:白細胞降低I度2例、II度1例,血小闆降低I度1例、II度1例;放射性肺炎III級9例。結論:伽馬刀聯閤複方紅豆杉膠囊治療高齡晚期非小細胞肺癌有效,可延長患者生存期,不良反應可接受。
목적:분석가마도연합복방홍두삼효낭치료고령만기비소세포폐암적료효。방법:2008년1월지2011년11월기간,아원수치적고령만기비소세포폐암15례채용가마도치료+복방홍두삼효낭0.6g구복3차/일,21천위1료정,차후매월안료정련속구복。가마도치료이50%~80%등제량곡선위처방제량선,평균제량(45.1667±4.7346)Gy/(6~14)f,3.5~8Gy/f,5f/w,1f/d。치료결속후,매1~3월복사혈상규、혈생화、종류표지물급영상학검사。수방3~60개월지2013년9월결속。결과:국부유효솔( CR+PR)95.83%,중위생존기18개월(6~60개월),1、2、3、4、5년생존솔분별위66.7%、33.3%、33.3%、6.7%、6.7%。소화도반응:I도1례、II도3례;혈액학독성:백세포강저I도2례、II도1례,혈소판강저I도1례、II도1례;방사성폐염III급9례。결론:가마도연합복방홍두삼효낭치료고령만기비소세포폐암유효,가연장환자생존기,불량반응가접수。
Objective:To analyze the effectiveness of Gama-knife combined with Hongdoushan capsules in the treatment of elderly patients with advanced non-small cell lung cancer. Methods:From Jan. 2008 to Nov. 2011 in our hospital,15 elderly patients with advanced non-small cell lung cancer accepted the treatment of Gama-knife and Hongdoushan capsules of the dose of 0. 6g 3/d and 21 days as a course which orally administrated without stop monthly. A 30~56Gy total dose were prescribed to the 50% ~80% isodoseline and in 6~14 fraction of 3. 5~8Gy each for target with one week five times and one day one time for the Gama-knife treatment. Blood routine,blood bio-chemistry,tumor markers and imaging examinations were taken on the patients every 1~3 months after treatment. The follow-up time was 3~60 months and ended in Sep. 2013. Results:The local tumors'response rate(CR+PR)was 95. 83%. The overall survival time was 6~60 months with a median survival time of 18 months,and the 1-,2-, 3-,4-,5 -year survival rate was 66. 7%,33. 3%,33. 3%,6. 7%,and 6. 7% respectively. For digestive side effect,1 case was grade I,3 was II,for haematological toxicity,2 cases occurred grade I white cell reduction,1 was II and 1 case occurred grade I blood platelets reduction,1 was II,9 cases occurred grade III radiation pneumonitis. Con-clusion:Gama-knife combined with Hongdoushan capsules treatment is effective for elderly patients with advanced non-small cell lung cancer with an acceptable toxicity and it can prolong the patients' survival time.